Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 7 | 2022 | 44 | 1.020 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2023 | 10 | 0.480 |
Why?
|
| Hemorrhage | 6 | 2021 | 78 | 0.370 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 36 | 0.370 |
Why?
|
| Heparin | 2 | 2020 | 17 | 0.360 |
Why?
|
| Hemophilia B | 3 | 2020 | 10 | 0.350 |
Why?
|
| Anticoagulants | 2 | 2020 | 89 | 0.330 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 1 | 0.310 |
Why?
|
| Factor VIII | 5 | 2023 | 30 | 0.310 |
Why?
|
| Factor IX | 2 | 2020 | 7 | 0.310 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 21 | 0.310 |
Why?
|
| Thrombophilia | 2 | 2020 | 5 | 0.240 |
Why?
|
| Hemostasis | 2 | 2016 | 8 | 0.230 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 14 | 0.230 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2004 | 14 | 0.230 |
Why?
|
| Hemostatics | 1 | 2023 | 10 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2020 | 25 | 0.210 |
Why?
|
| Sex Chromosome Disorders | 1 | 2022 | 1 | 0.210 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 4 | 0.200 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 11 | 0.200 |
Why?
|
| Humans | 21 | 2023 | 26246 | 0.190 |
Why?
|
| Physical Therapists | 1 | 2021 | 3 | 0.180 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 5 | 0.180 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 32 | 0.180 |
Why?
|
| Serum Albumin | 1 | 2020 | 21 | 0.180 |
Why?
|
| Young Adult | 6 | 2023 | 1888 | 0.160 |
Why?
|
| Health Literacy | 1 | 2021 | 105 | 0.160 |
Why?
|
| Adolescent | 6 | 2023 | 2080 | 0.160 |
Why?
|
| Adult | 10 | 2023 | 7441 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 14 | 0.160 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 13 | 0.160 |
Why?
|
| Joint Diseases | 1 | 2018 | 108 | 0.140 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Albumins | 1 | 2016 | 18 | 0.130 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 200 | 0.130 |
Why?
|
| Child | 4 | 2023 | 1234 | 0.120 |
Why?
|
| Blood Coagulation Factors | 2 | 2006 | 17 | 0.120 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2012 | 621 | 0.120 |
Why?
|
| Autoantibodies | 2 | 2006 | 71 | 0.120 |
Why?
|
| Autoimmune Diseases | 2 | 2006 | 39 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2012 | 790 | 0.110 |
Why?
|
| von Willebrand Factor | 3 | 2023 | 9 | 0.100 |
Why?
|
| Male | 8 | 2023 | 14117 | 0.100 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 55 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 104 | 0.080 |
Why?
|
| Middle Aged | 5 | 2020 | 8589 | 0.080 |
Why?
|
| Female | 6 | 2023 | 14509 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 16 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2008 | 16 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2008 | 37 | 0.080 |
Why?
|
| Liver | 1 | 2008 | 123 | 0.070 |
Why?
|
| United States | 3 | 2018 | 1991 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 215 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 2271 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 7 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 27 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 73 | 0.060 |
Why?
|
| Fever | 1 | 2005 | 35 | 0.060 |
Why?
|
| Pneumonectomy | 1 | 2006 | 67 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 3 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 2 | 0.060 |
Why?
|
| Trophoblasts | 1 | 2004 | 2 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 124 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 102 | 0.060 |
Why?
|
| Quality of Life | 2 | 2020 | 620 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 347 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 58 | 0.060 |
Why?
|
| Hemorrhagic Disorders | 1 | 2004 | 1 | 0.060 |
Why?
|
| Paraproteins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Fibrin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 116 | 0.060 |
Why?
|
| Biopolymers | 1 | 2004 | 6 | 0.060 |
Why?
|
| Autoantigens | 1 | 2004 | 23 | 0.060 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 5 | 0.060 |
Why?
|
| Plasma | 1 | 2023 | 17 | 0.060 |
Why?
|
| Apoptosis | 1 | 2004 | 193 | 0.060 |
Why?
|
| Pregnancy | 2 | 2020 | 311 | 0.060 |
Why?
|
| Comorbidity | 2 | 2018 | 475 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1075 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2023 | 39 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 87 | 0.050 |
Why?
|
| Elective Surgical Procedures | 2 | 2012 | 38 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2023 | 592 | 0.050 |
Why?
|
| Hemarthrosis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Aged | 3 | 2020 | 8754 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 3 | 0.050 |
Why?
|
| North America | 1 | 2020 | 38 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 507 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 47 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 378 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 1 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 2 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 3 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 1735 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 3365 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 109 | 0.040 |
Why?
|
| Anxiety | 1 | 2018 | 136 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 21 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 4 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2016 | 11 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 71 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 51 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 315 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2016 | 96 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 855 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 290 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 4675 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 409 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 495 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2016 | 3381 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2011 | 17 | 0.020 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2011 | 7 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 13 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 8 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 2011 | 21 | 0.020 |
Why?
|
| Cell Division | 1 | 2011 | 79 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 44 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 109 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 1673 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 222 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 264 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 294 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 305 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 370 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 1282 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2006 | 4 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 23 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 15 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2006 | 42 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 49 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2006 | 28 | 0.020 |
Why?
|
| Prednisone | 1 | 2006 | 61 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 866 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2005 | 1 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2005 | 20 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 280 | 0.020 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 7 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 26 | 0.020 |
Why?
|
| Placenta | 1 | 2004 | 10 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 25 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 124 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 314 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 91 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 79 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 184 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 224 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 475 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 3396 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 174 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 226 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 485 | 0.010 |
Why?
|